Key facts
| Price (PPV) | 11,182 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | lapatinib |
| Class | Antineoplastic agents |
| ATC code | L01EH01 |
| Manufacturer | NOVARTIS PHARMA MAROC |
| Presentation | Boîte de 70 |
| Nature | Médicament |
| Hospital price | 10,971 MAD |
| Data collected on | 9/8/2026 |
Indications
Traitement du cancer du sein, en association avec la capécitabine, chez les patientes atteintes d'un cancer du sein avancé ou métastatique avec surexpression des récepteurs ErbB2 (HER2) et progression de la maladie après un traitement précédent par le trastuzumab au stade métastatique. Source : Compendium.ch - Date : 20 octobre 2025
Find an open pharmacy
On-call pharmacies near you
About Tykerb 250 mg
Tykerb 250 mg belongs to the antineoplastic agents therapeutic class. In Morocco, this drug is marketed by NOVARTIS PHARMA MAROC and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Tykerb 250 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Tykerb 250 mg
Answers to common questions from Moroccan patients about this drug.